Will CEO Grossman become a net seller of ADMA shares by year-end 2026?
Current Prediction
Why This Question Matters
CEO Grossman's net accumulation during the 29% decline was identified as the strongest counter-signal to fraud allegations. Fraudulent executives rarely buy stock with personal capital during a crisis. A shift to net selling in 2026 would undermine this counter-signal and trigger a governance downgrade. Continued buying would further reduce the probability of the most extreme short seller claims.
Prediction Distribution
Individual Predictions(9 runs)
CEO Grossman established a 10b5-1 plan in November 2025 and has been a net accumulator of +98,927 shares during a 29% decline. This is a strong signal of conviction. Shifting to net selling would require either (1) a genuine change in his view of the company, (2) personal financial needs, or (3) tax planning as options vest. The 10b5-1 plan includes option exercises with partial sales which are mechanical, not discretionary. For NET selling to occur, the mechanical sales from option exercises would need to significantly exceed any purchases. Given his demonstrated accumulation pattern and the 10b5-1 structure, a shift to net selling by year-end 2026 is unlikely but possible if stock recovers significantly and tax optimization becomes primary.
The question covers all of 2026, a long window. Option vesting schedules could create mechanical selling pressure. However, Grossman demonstrated willingness to hold and accumulate during peak controversy. A CEO who buys during a 29% crash is unlikely to become a net seller absent a fundamental change in outlook. The key risk is a large option exercise block vesting in 2026 that triggers substantial tax-driven sales. Proposed Form 144 filings show 294,000 shares ($5.1M) in planned sales which are relatively modest relative to his holdings. Low probability.
CEOs who accumulate during crises rarely reverse within a year unless business fundamentals deteriorate significantly. Given that the committee found ASCENIV differentiation genuine and management guidance aggressive ($635M+ FY2026), the fundamental outlook does not support a shift to selling. The 10b5-1 plan creates a structure for orderly transactions, not aggressive liquidation. Even if some option exercises generate sales, Grossman pattern suggests he would offset with market purchases. Low probability.
While Grossman has been a strong net buyer, 10b5-1 plans are designed for systematic sales. The proposed Form 144 filings show 294,000 shares planned for sale. If these execute and no offsetting purchases are made, they would significantly exceed the +98,927 net accumulation. The question is whether Grossman will make additional purchases to maintain his net buyer status. If stock price recovers and the crisis abates, the incentive to signal conviction through buying diminishes. Moderate-low probability as the planned sales could mechanically tip the balance.
The resolution criteria specifies net shares sold exceeding net shares acquired (excluding option exercises that are immediately held). This exclusion is important as it means pure option-exercise-and-hold transactions do not count toward selling. Only discretionary sales or exercise-and-sell transactions count. Given Grossman demonstrated accumulation behavior and the signal value of maintaining net buyer status, I expect him to manage his transactions to remain net positive. But tax-driven sales from large option blocks could force the issue. Low probability.
CEO insider behavior following short seller reports is a well-studied pattern. CEOs who buy during crises (especially via pre-established 10b5-1 plans) tend to continue holding or buying to maintain the signal. Grossman behavior is consistent with genuine conviction rather than signaling alone. $5.1M in planned sales against a demonstrated accumulation pattern suggests orderly portfolio management, not a shift in direction. The 2026 resolution window is long but Grossman incentives favor continued accumulation or at minimum neutral positioning.
CEO bought +98,927 shares during 29% decline. Strong conviction signal. 10b5-1 plan includes systematic sales but CEO has incentive to remain net buyer. Planned sales of 294,000 shares could mechanically shift to net seller but CEO likely to offset. Low probability.
CEOs who accumulate during crises rarely reverse within one year. Fundamental outlook supports continued confidence. 10b5-1 sales are mechanical and modest. No evidence of shifting sentiment. Low probability of becoming net seller.
The full-year 2026 window is the main risk factor. Option exercises and tax planning could generate mechanical sales. But CEO demonstrated pattern and signaling incentives favor maintaining net buyer status. Low probability overall.
Resolution Criteria
Resolves YES if cumulative Form 4 filings for CEO Adam Grossman from January 1 to December 31, 2026 show net shares sold exceeding net shares acquired (excluding option exercises that are immediately held). Resolves NO if Grossman remains a net buyer or neutral through 2026.
Resolution Source
SEC Form 4 filings for Adam Grossman at ADMA Biologics
Source Trigger
CEO Insider Direction — Shift to net selling = downgrade
Full multi-lens equity analysis